INDGN578.00

Indegene Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSYNGENELTTSGRANULESJUBLPHARMAKIMSERISEMCUREONESOURCEMcap ₹13,901 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations673.0676.5686.8720.4755.6760.8804.2942.11,003.41,063.1
Other Income23.222.521.437.725.622.119.719.410.829.0
Total Income696.2699.0708.2758.1781.2782.9823.9961.51,014.21,092.1
Expenses
+ Employee Benefit Expense428.4444.3442.0443.8485.1481.5515.8568.0632.4659.1
+ Finance Costs12.311.74.03.23.13.73.84.67.26.4
+ Depreciation & Amortisation18.520.119.420.020.721.623.439.641.844.1
+ Other Expenses105.9103.3118.7144.8123.0124.0147.8214.6207.4229.8
Total Expenses565.1579.4584.1611.8631.9630.8690.8826.8888.8939.4
EBITDA138.7128.9126.1131.8147.5155.3140.6159.5163.6174.2
EBIT120.2108.8106.7111.8126.8133.7117.2119.9121.8130.1
Profit
PBT before Exceptional Items131.1119.6124.1146.3149.3152.1133.1134.7125.4152.7
+ Exceptional Items2.40.00.00.00.00.00.00.0-20.30.0
Pretax Income133.5119.6124.1146.3149.3152.1133.1134.7105.1152.7
+ Current Tax13.135.236.333.843.828.437.987.422.629.3
+ Deferred Tax25.6-3.3-3.92.8-12.17.3-6.9-55.62.87.2
Tax Expense38.731.932.436.631.735.731.031.825.436.5
Net Income94.887.791.7109.7117.6116.4102.1102.979.7116.2
+ Net Income — Continuing Ops94.887.791.7109.7117.6116.4102.1102.979.7116.2
+ Other Comprehensive Income1.8-0.810.613.22.616.748.419.355.011.8
Total Comprehensive Income96.686.9102.3122.9120.2133.1150.5122.2134.7128.0
Net Income to Common96.687.791.7109.7116.40.0102.979.7116.2
Per Share
Basic EPS4.273.793.844.594.914.864.264.293.324.84
Diluted EPS4.243.763.804.554.884.824.234.263.304.81
Other Comprehensive Income — detail
+ Other Comprehensive Income2.616.748.419.355.011.8
+ Items NOT to be Reclassified to P&L-0.21.5-0.81.1-3.91.22.40.6-0.1-2.9
+ Tax on Items NOT to be Reclassified-1.00.30.60.2-0.1-0.7
+ Tax on Items NOT to be Reclassified — alt tag-0.10.4-0.20.3
+ Items to be Reclassified to P&L1.9-1.911.212.45.515.846.618.953.315.5
+ Tax on Items to be Reclassified0.00.00.00.0-1.71.5
Comprehensive Income — Owners of Parent1.886.9102.3122.9120.216.7102.1122.255.011.8
Comprehensive Income — Non-controlling Interests0.00.00.00.00.0133.10.00.00.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations4.273.793.844.594.914.864.264.293.324.84
Diluted EPS — Continuing Operations4.243.763.804.554.884.824.234.263.304.81
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit673.0676.5686.8720.4755.6760.8804.2942.11,003.41,063.1
Gross Margin %100.00100.00100.00100.00100.00100.00100.00100.00100.00100.00
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)131.1119.6124.1146.3149.3152.1133.1134.7125.4152.7
− Exceptional Items (reconciliation)2.40.00.00.00.00.00.00.0-20.30.0
Net Income Adj (tax-effected)93.187.791.7109.7117.6116.4102.1102.995.1116.2
EPS Adj4.193.793.844.594.914.864.264.293.964.84
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value2.002.002.002.002.002.002.002.002.002.00
Paid Up Equity Capital44.447.947.847.847.947.948.048.048.148.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.